Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Eton Pharmaceuticals, Inc. (ETON : NSDQ)
 
 • Company Description   
Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois.

Number of Employees: 31

 
 • Price / Volume Information   
Yesterday's Closing Price: $15.56 Daily Weekly Monthly
20 Day Moving Average: 588,523 shares
Shares Outstanding: 26.82 (millions)
Market Capitalization: $417.28 (millions)
Beta: 1.18
52 Week High: $21.48
52 Week Low: $3.25
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 7.24% 3.22%
12 Week 8.51% -8.73%
Year To Date 16.82% 9.40%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
21925 W. FIELD PARKWAY SUITE 235
-
DEER PARK,IL 60010
USA		 ph: 847-787-7361
fax: -		 investorrelations@etonpharma.com http://www.etonpharma.com
 
 • General Corporate Information   
Officers
Sean E. Brynjelsen - Chief Executive Officer;President and Director
James Gruber - Chief Financial Officer; Treasurer and Secretary
Jennifer M. Adams - Director
Charles J. Casamento - Director
Paul V. Maier - Director

Peer Information
Eton Pharmaceuticals, Inc. (CORR.)
Eton Pharmaceuticals, Inc. (RSPI)
Eton Pharmaceuticals, Inc. (CGXP)
Eton Pharmaceuticals, Inc. (BGEN)
Eton Pharmaceuticals, Inc. (GTBP)
Eton Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29772L108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 26.82
Most Recent Split Date: (:1)
Beta: 1.18
Market Capitalization: $417.28 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.14 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.44 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 35.36
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 17.07
Price/Cash Flow: -
Price / Sales: 8.63
EPS Growth
vs. Year Ago Period: 333.33%
vs. Previous Quarter: 450.00%
Sales Growth
vs. Year Ago Period: 116.95%
vs. Previous Quarter: 48.38%
ROE
06/30/25 - -
03/31/25 - -3.15
12/31/24 - -22.05
ROA
06/30/25 - -
03/31/25 - -1.08
12/31/24 - -8.76
Current Ratio
06/30/25 - -
03/31/25 - 1.97
12/31/24 - 2.06
Quick Ratio
06/30/25 - -
03/31/25 - 1.43
12/31/24 - 1.29
Operating Margin
06/30/25 - -
03/31/25 - -1.28
12/31/24 - -9.80
Net Margin
06/30/25 - -
03/31/25 - -9.49
12/31/24 - -9.80
Pre-Tax Margin
06/30/25 - -
03/31/25 - -9.30
12/31/24 - -9.76
Book Value
06/30/25 - -
03/31/25 - 0.91
12/31/24 - 0.94
Inventory Turnover
06/30/25 - -
03/31/25 - 2.44
12/31/24 - 2.89
Debt-to-Equity
06/30/25 - -
03/31/25 - 1.23
12/31/24 - 1.22
Debt-to-Capital
06/30/25 - -
03/31/25 - 55.09
12/31/24 - 54.96
 

Powered by Zacks Investment Research ©